In this issue:
STIC increases risk of post-rrBSO PC in BRCA1/2 variant carriers
ARIEL4: Rucaparib extends PFS for relapsed BRCA-mutated OC
Olaparib ± cediranib does not extend PFS vs chemotherapy in recurrent PS disease
pCR prognostic for better outcomes after interval surgery
Secondary cytoreductive surgery prolongs survival in PS recurrent OC
Addition of olaparib to frontline maintenance confers PFS advantage
Racial/ethnic enrolment disparities in clinical trials of PARP inhibitors
Secondary cytoreductive surgery after interval debulking for PS recurrent OC
Role of tertiary cytoreductive surgery in recurrent OC
Evaluation of residual disease improved by use of post-surgical CT
MAPK mutations prognostic for superior survival in LGSOC
TCGA molecular classification prognostic for clear cell OC
Please login below to download this issue (PDF)